Chimera Bioengineering
Christina Smolke has extensive work experience in the field of bioengineering. Christina is the CEO & Co-Founder of Antheia, Inc., a role they have held since April 2015. Christina is also a Co-Founder of Chimera Bioengineering since 2015. Prior to their entrepreneurial ventures, Christina worked as a Professor at Stanford University starting from January 2009. Before that, they served as an Assistant Professor at Caltech from December 2003 to December 2008.
Christina Smolke pursued their education starting in 1993 at the University of Southern California, where they obtained a Bachelor of Science (BS) degree in Chemical Engineering in 1997. Christina then went on to continue their studies at the University of California, Berkeley, beginning in 1997. There, they completed their Doctor of Philosophy (PhD) in Chemical Engineering in 2001. Following their PhD, they pursued a Postdoctorate at the University of California, Berkeley from 2001 to 2003, focusing on Molecular and Cellular Biology.
This person is not in any teams
Chimera Bioengineering
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia andlymphoma, have shown transformative results for patients unresponsive to standard therapy.However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients.Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w